Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact

Julia Ml Brotherton; David Hawkes; Farhana Sultana; Michael J Malloy; Dorothy A Machalek; Megan A Smith; Suzanne M Garland; Marion Saville

doi:10.1016/j.vaccine.2018.11.075

Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact

Vaccine. 2019 Jan 14;37(3):412-416. doi: 10.1016/j.vaccine.2018.11.075. Epub 2018 Dec 11.

Authors

Julia Ml Brotherton¹, David Hawkes², Farhana Sultana³, Michael J Malloy⁴, Dorothy A Machalek⁵, Megan A Smith⁶, Suzanne M Garland⁷, Marion Saville⁸

Affiliations

¹ VCS Population Health, VCS Foundation, Level 6, 176 Wellington Parade, East Melbourne, VIC, 3002, Australia; Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Victoria 3053, Australia. Electronic address: [email protected].
² VCS Pathology, VCS Foundation, 265 Faraday Street, Carlton South, Victoria 3053, Australia; Department of Pharmacology and Therapeutics, The University of Melbourne, Victoria 3010, Australia. Electronic address: [email protected].
³ VCS Population Health, VCS Foundation, Level 6, 176 Wellington Parade, East Melbourne, VIC, 3002, Australia; Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Victoria 3053, Australia. Electronic address: [email protected].
⁴ VCS Population Health, VCS Foundation, Level 6, 176 Wellington Parade, East Melbourne, VIC, 3002, Australia; Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Victoria 3053, Australia. Electronic address: [email protected].
⁵ Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Victoria 3053, Australia; Centre for Women's Infectious Diseases, The Royal Women's Hospital, Cnr Grattan St & Flemington Rd, Parkville, Victoria 3052, Australia; Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Electronic address: [email protected].
⁶ Cancer Research Division, Cancer Council NSW, 153 Dowling St, Woolloomooloo, NSW 2011, Australia. Electronic address: [email protected].
⁷ Centre for Women's Infectious Diseases, The Royal Women's Hospital, Cnr Grattan St & Flemington Rd, Parkville, Victoria 3052, Australia; Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: [email protected].
⁸ VCS Pathology, VCS Foundation, 265 Faraday Street, Carlton South, Victoria 3053, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: [email protected].

PMID: 30551987
DOI: 10.1016/j.vaccine.2018.11.075

Abstract

Australia's transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25-74, 9.25% (95%CI: 9.09-9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05-2.22%) were 16/18 positive and 7.12% (95%CI: 6.97-7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25-29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence.

Keywords: Australia; Cervical screening; Human papillomavirus; Prevalence.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Age Factors*
Aged
Australia / epidemiology
Cervix Uteri / virology*
Early Detection of Cancer
Female
Genotype
Human papillomavirus 16
Human papillomavirus 18
Humans
Mass Screening / statistics & numerical data*
Middle Aged
Papillomaviridae / genetics
Papillomavirus Infections / epidemiology*
Papillomavirus Infections / prevention & control
Papillomavirus Vaccines / therapeutic use*
Prevalence
Uterine Cervical Dysplasia / prevention & control
Uterine Cervical Dysplasia / virology
Uterine Cervical Neoplasms / prevention & control
Vaccination / statistics & numerical data*

Substances

Papillomavirus Vaccines